Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT02772601 Completed - Psoriasis Clinical Trials

This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

Start date: September 15, 2016
Phase: Phase 1
Study type: Interventional

To assess the influence of risankizumab on kinetics of cytochrome P450 (CYP) probe drugs as a means of predicting drug-drug interactions.

NCT ID: NCT02763969 Completed - Psoriasis Clinical Trials

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Start date: May 18, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to establish if BMS-986202 is safe and effective at treating autoimmune diseases such as psoriasis. BMS-986202 which has shown some promise in preclinical studies for inhibiting autoimmune conditions such as psoriasis. This study will be the first time this drug is given to humans.

NCT ID: NCT02762994 Completed - Psoriasis Clinical Trials

International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis

Start date: June 2016
Phase: Phase 2
Study type: Interventional

BCD-085-2 is a next step in clinical investigation of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-2 trial patients with moderate to severe plaque psoriasis, in whom poor response to previous treatment including UV-therapy and biologic drugs was registered, will receive 40, 80 or 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10. Efficacy and safety parameters will be evaluated.

NCT ID: NCT02762955 Completed - Psoriasis Clinical Trials

Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis

CALYPSO
Start date: December 2016
Phase: Phase 3
Study type: Interventional

CALYPSO clinical study is a phase 3 study which is carried out to establish the efficacy, safety and pharmacokinetic equivalence of BCD-055 (adalimumab, manufactured by JSC BIOCAD, Russia) and Humira® when used in patients with moderate to severe plaque psoriasis.

NCT ID: NCT02752776 Completed - Plaque Psoriasis Clinical Trials

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

PROSE
Start date: March 17, 2016
Phase: Phase 4
Study type: Interventional

Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.

NCT ID: NCT02752672 Completed - Psoriasis Clinical Trials

Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis

Start date: March 2016
Phase: N/A
Study type: Observational

Dithranol (known in the U.S.A. as anthralin and in Germany as cignolin) is one of the oldest and safest topical anti-psoriatic treatments. However, despite explorative investigations, the skin disease-clearing mechanisms of dithranol remain poorly understood (Painsi et al, JDDG 2015). The purpose of this study is to investigate the therapeutic mechanisms of dithranol in psoriasis.

NCT ID: NCT02750800 Completed - Clinical trials for Rheumatoid Arthritis

Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)

VALUE
Start date: April 7, 2016
Phase:
Study type: Observational

The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (Ps), Crohn's disease (CD) or ulcerative colitis (UC) in the routine clinical setting in Hungary.

NCT ID: NCT02749799 Completed - Plaque Psoriasis Clinical Trials

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

Start date: February 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.

NCT ID: NCT02749370 Completed - Plaque Psoriasis Clinical Trials

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

Start date: May 18, 2016
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).

NCT ID: NCT02748863 Completed - Psoriasis Clinical Trials

Study of Secukinumab With 2 mL Pre-filled Syringes

ALLURE
Start date: December 12, 2016
Phase: Phase 3
Study type: Interventional

The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.